Jeffrey M. Axten

3.1k citations

29 papers · 1.9k indexed · 2 hit papers · h-index 16

Co-authors: Jeffrey D. Winkler Claudio Hetz John B. Patterson David A. Barrett Catharine A. Ortori Colin Molloy Anne E. Willis Nicholas Verity
Topics: Endoplasmic Reticulum Stress and Disease (8 papers)Autophagy in Disease and Therapy (5 papers)Chemical Synthesis and Analysis (4 papers)
Cited by: Cell Biology Aging Biotechnology
Journals: Journal of the American Chemical Society Cancer Research Biochemical Journal
Partner nations: United States United Kingdom Chile

In The Last Decade

Jeffrey M. Axten

29 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

2013 453 citations Jeffrey M. Axten et al. profile →
Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

2013 364 citations Charity Atkins, Qi Liu et al. Cancer Research profile →

Peers

Countries citing papers authored by Jeffrey M. Axten

Since Specialization

Citations

This map shows the geographic impact of Jeffrey M. Axten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey M. Axten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey M. Axten more than expected).

Fields of papers citing papers by Jeffrey M. Axten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey M. Axten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey M. Axten. The network helps show where Jeffrey M. Axten may publish in the future.

Co-authorship network of co-authors of Jeffrey M. Axten

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey M. Axten. A scholar is included among the top collaborators of Jeffrey M. Axten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey M. Axten. Jeffrey M. Axten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease 2022 ·Cell chemical biology ·(unknown),James Reihill,Melisa W-Y. Ho,Jeffrey M. Axten,Nino Campobasso,Jessica L. Schneck,Alan R. Rendina,Keith Wilcoxen,Lorraine Martin	18
2	Pharmacological targeting of the unfolded protein response for disease intervention 2019 ·Nature Chemical Biology ·Claudio Hetz,Jeffrey M. Axten,John B. Patterson	196
3	An efficient and practical synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones 2019 ·Tetrahedron Letters ·Xinrong Tian,Dominic Suarez,(unknown),(unknown),(unknown),Michael L. Moore,Jeffrey M. Axten	2
4	Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease 2018 ·Neurobiology of Disease ·Gabriela Mercado,Valentina Castillo,Paulina Soto,(unknown),Jeffrey M. Axten,S. Pablo Sardi,Jeroen J.M. Hoozemans,Claudio Hetz	128
5	PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome 2018 ·Human Molecular Genetics ·(unknown),Francesca Ornaghi,(unknown),Elena Restelli,(unknown),Alessandro Corbelli,Daniele Tolomeo,(unknown),Jeffrey M. Axten,Nicholas J. Laping,Fabio Fiordaliso,Michele Sallese,Roberto Chiesa	41
6	TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis 2017 ·Blood Advances ·Nicholas J. Laping,Michael P. DeMartino,Joshua E. Cottom,Jeffrey M. Axten,John G. Emery,Jeffrey Guss,Miriam Burman,James J. Foley,Mui Cheung,Allen Oliff,Sanjay Kumar	2
7	Protein kinase R(PKR)–like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015) 2016 ·Expert Opinion on Therapeutic Patents ·Jeffrey M. Axten	24
8	Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activitybreakdown → 2013 ·Cancer Research ·Charity Atkins,Qi Liu,Elisabeth A. Minthorn,ShuYun Zhang,David J. Figueroa,Katherine G. Moss,Thomas B. Stanley,Brent Sanders,Aaron S. Goetz,(unknown),Anthony E. Choudhry,Hasan Alsaid,Beat M. Jucker,Jeffrey M. Axten,Rakesh Kumar	364
9	Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells 2013 ·Cancer Chemotherapy and Pharmacology ·Huaping Liu,Metin Kurtoğlu,(unknown),Haibin Xi,Rakesh Kumar,Jeffrey M. Axten,Théodore J. Lampidis	19
10	Acylprolinamides: A new class of peptide deformylase inhibitors with in vivo antibacterial activity 2012 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey M. Axten,Jesús R. Medina,Charles W. Blackledge,Céline Duquenne,Seth W. Grant,Mark A. Bobko,(unknown),William H. Miller,(unknown),Timothy F. Gallagher,Swarupa G. Kulkarni,(unknown),Glenn S. Van Aller,(unknown),Paris Ward,Nino Campobasso	5
11	Rapid synthesis of diversely functionalized 3,4,7-trisubstituted indoles 2011 ·Tetrahedron Letters ·Seth W. Grant,Timothy F. Gallagher,Mark A. Bobko,Céline Duquenne,Jeffrey M. Axten	6
12	Discovery of a new series of Aurora inhibitors through truncation of GSK1070916 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jesús R. Medina,Seth W. Grant,Jeffrey M. Axten,William H. Miller,Carla A. Donatelli,Mary Ann Hardwicke,Catherine A. Oleykowski,(unknown),Ramona Plant,Hong Xiang	13
13	A novel method for the 1,2-carbonyl transposition of pleuromutilins 2010 ·Tetrahedron Letters ·Céline Duquenne,Timothy F. Gallagher,Jeffrey M. Axten	4
14	Abstract LB-42: PDK1 knockdown selectively inhibits growth of cancer cells harboring activating mutations involved in MAPK signaling 2010 ·Cancer Research ·M. Phillip DeYoung,Christine Gardiner,(unknown),Jesús R. Medina,Jeffrey M. Axten,Sridhar K. Rabindran	2
15	Benzyl 2-Cyano-3,3-Dimethyl-1-pyrrolidinecarboxylate, a Versatile Intermediate for the Synthesis of 3,3-Dimethylproline Derivatives 2008 ·The Journal of Organic Chemistry ·Jesús R. Medina,Charles W. Blackledge,Karl F. Erhard,Jeffrey M. Axten,William H. Miller	6
16	A mild and general method for the synthesis of 2-substituted-5-hydroxypyrimidines 2006 ·Tetrahedron Letters ·Jesús R. Medina,(unknown),Jeffrey M. Axten	3
17	The First Total Syntheses of Ircinol A, Ircinal A, and Manzamines A and D 1998 ·Journal of the American Chemical Society ·Jeffrey D. Winkler,Jeffrey M. Axten	127
18	Stereoselective synthesis of the tetracyclic core of manzamine via the vinylogous amide photocycloaddition cascade 1998 ·Tetrahedron ·Jeffrey D. Winkler,Jeffrey M. Axten,(unknown),Young‐Shin Kwak,Urs D. Lengweiler,Melissa J. Lucero,K. N. Houk	21
19	An ab initio molecular orbital study of the grignard reagents CH3MgCl and [CH3MgCl]2: The Schlenk equilibrium 1994 ·Structural Chemistry ·Jeffrey M. Axten,(unknown),Peter Jiang,Mendel Trachtman,Charles W. Bock	15
20	Synthesis and Characterization of Novel Ferrocenyl-Substituted Pyrroles 1992 ·Synthetic Communications ·(unknown),Mark E. McDonnell,Jeffrey M. Axten,Leonard J. Buckley	8

About Jeffrey M. Axten

Jeffrey M. Axten is a scholar working on Cell Biology, Biotechnology and Organic Chemistry, having authored 29 papers that have together received 1.9k indexed citations. Recurring topics across this work include Endoplasmic Reticulum Stress and Disease (8 papers), Autophagy in Disease and Therapy (5 papers) and Chemical Synthesis and Analysis (4 papers). The work is most often cited by research in Cell Biology (998 citations), Aging (31 citations) and Biotechnology (138 citations). Jeffrey M. Axten has collaborated with scholars based in United States, United Kingdom and Chile. Frequent co-authors include Jeffrey D. Winkler, Claudio Hetz, John B. Patterson, David A. Barrett, Catharine A. Ortori, Colin Molloy, Anne E. Willis, Nicholas Verity, Julie A. Moreno and Giovanna R. Mallucci. Their work appears in journals such as Journal of the American Chemical Society, Cancer Research and Biochemical Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact